(C) 2011 American Institute of Physics [doi:10 1063/1 3653285]“<

(C) 2011 American Institute of Physics. [doi:10.1063/1.3653285]“
“A new Staphylococcus xylosus strain was isolated. The extracellular lipase of S. xylosus DNA Synthesis inhibitor (wt-SXL2) was purified to homogeneity from the culture medium. The specific activity of the purified enzyme, measured at pH 8.5 and 55 degrees C using tributyrin or olive oil emulsion, reached, respectively, 6300 U/mg or 2850 U/mg. The sequenced 18 N-terminal amino acid showed a high degree

of identity with known staphylococcal lipase sequences.

The gene encoding the mature lipase was cloned and sequenced. The deduced amino acid sequence showed a significant similarity with various staphylococcal lipases. The highest overall identity (98.74%) was found with S. xylosus lipase (SXL1). The mature part of the lipase was expressed in Escherichia coli. The LB-100 datasheet recombinant lipase was purified by affinity chromatography. The specific activity of the recombinant

lipase was 4100 or 1500 U/mg using tributyrin or olive oil emulsion as substrate, respectively, at pH 8.5 and 55 degrees C.

The wild type and recombinant lipases presented a quite interesting thermal stability, after an incubation of 60 min at 55 degrees C and they are found to be highly stable at a pH ranging from 4 to 11. Due to its stability at high temperature and in organic solvent, the wt-SXL2 was used as biocatalyst to synthesise a high added value molecules. (C) 2011 Elsevier B.V. All rights reserved.”

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to cam CME credit. This activity has been planned and implemented

in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education Tozasertib in vivo for physicians Medscape, LLC designates this educational activity for a maximum of 0.75 A AM PRA Category 1 Credits (TM), Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures (2) study the education content (3) take the post-test and/or complete the evaluation at http://www.medscape.com/cme/eid; (4) view/print certificate.

No related posts.

Comments are closed.